These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3045105)

  • 1. Oral dyskinesia associated with buspirone use in an elderly woman.
    Strauss A
    J Clin Psychiatry; 1988 Aug; 49(8):322-3. PubMed ID: 3045105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent movement disorders induced by buspirone.
    LeWitt PA; Walters A; Hening W; McHale D
    Mov Disord; 1993 Jul; 8(3):331-4. PubMed ID: 8101969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buspirone revisited.
    Lydiard RB
    J Clin Psychiatry; 1989 Aug; 50(8):308. PubMed ID: 2569458
    [No Abstract]   [Full Text] [Related]  

  • 4. Buspirone and dyskinesia.
    Simpson GM; Singh H
    J Clin Psychiatry; 1988 Dec; 49(12):503. PubMed ID: 3198582
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral dyskinesia induced by tryptizol.
    Duxbury AJ; Leach FN; Smart TE
    Dent Update; 1982 Jun; 9(5):299-302. PubMed ID: 6959934
    [No Abstract]   [Full Text] [Related]  

  • 6. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenates.
    Huang NY; Kostrzewa RM; Li C; Perry KW; Fuller RW
    J Pharmacol Exp Ther; 1997 Jan; 280(1):268-76. PubMed ID: 8996206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Movement disorders and new azapirone anxiolytic drugs.
    Jann MW; Froemming JH; Borison RL
    J Am Board Fam Pract; 1990; 3(2):111-9. PubMed ID: 2185606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL; Gupta V; Alam S; Park JY; Bishop C
    Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible adverse effects of buspirone when used with other psychotropic drugs.
    Rock NL
    J Clin Psychopharmacol; 1990 Oct; 10(5):380-1. PubMed ID: 2258458
    [No Abstract]   [Full Text] [Related]  

  • 11. [Neuroleptic-induced movement disorders: historical perspectives].
    Wolf MA; Yassa R; Llorca PM
    Encephale; 1993; 19(6):657-61. PubMed ID: 12404786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
    Haleem DJ; Samad N; Haleem MA
    Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral dyskinesias induced and inhibited by 5-hydroxytryptamine injections into different parts of the rat brain.
    Sundén-Kuronen B; Pohto P; Alanen E
    Proc Finn Dent Soc; 1984; 80(2):67-72. PubMed ID: 6463038
    [No Abstract]   [Full Text] [Related]  

  • 14. Edentulous orodyskinesia.
    Koller WC
    Ann Neurol; 1983 Jan; 13(1):97-9. PubMed ID: 6830172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors?
    Crow TJ; Cross AJ; Johnstone EC; Owen F; Owens DG; Waddington JL
    J Clin Psychopharmacol; 1982 Oct; 2(5):336-40. PubMed ID: 7130435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroleptic treatment in the elderly.
    Zeman D
    Postgrad Med; 1995 Aug; 98(2):48. PubMed ID: 7630851
    [No Abstract]   [Full Text] [Related]  

  • 17. Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study.
    Haleem DJ; Samad N; Haleem MA
    Behav Pharmacol; 2007 Mar; 18(2):147-53. PubMed ID: 17351421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic stimulation of subthalamic nucleus elicits oral dyskinesia in rats.
    Parry TJ; Eberle-Wang K; Lucki I; Chesselet MF
    Exp Neurol; 1994 Aug; 128(2):181-90. PubMed ID: 7915675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model for oral dyskinesia in rats.
    Gunne LM; Growdon JH
    J Clin Psychopharmacol; 1982 Oct; 2(5):308-11. PubMed ID: 6290544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.